Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 3,385 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 3,385 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $22.60, for a total transaction of $76,501.00. Following the completion of the transaction, the chief financial officer directly owned 211,462 shares in the company, valued at $4,779,041.20. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Mountcastle also recently made the following trade(s):

• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
• On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total transaction of $179,690.37.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The shares were sold at an average price of $20.85, for a total transaction of $116,051.10.
• On Monday, March 16th, David Mountcastle sold 6,391 shares of Privia Health Group stock. The stock was sold at an average price of $22.11, for a total transaction of $141,305.01.
• On Friday, March 13th, David Mountcastle sold 6,565 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total transaction of $141,278.80.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The stock was sold at an average price of $21.90, for a total transaction of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The stock was sold at an average price of $22.84, for a total transaction of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The shares were sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Stock Down 1.7%

NASDAQ:PRVA opened at $22.63 on Thursday. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $26.51. The company has a market capitalization of $2.85 billion, a P/E ratio of 141.45, a P/E/G ratio of 1.69 and a beta of 0.96. The stock’s fifty day moving average is $22.65 and its two-hundred day moving average is $23.25.

Privia Health Group (NASDAQ:PRVA) last posted its earnings results on Thursday, May 7th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.11. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The company had revenue of $603.85 million for the quarter, compared to the consensus estimate of $560.99 million. During the same quarter in the previous year, the business earned $0.22 earnings per share. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. Sell-side analysts anticipate that Privia Health Group, Inc. will post 0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $36.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Barclays lifted their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Wednesday, March 25th. Evercore set a $26.00 target price on shares of Privia Health Group in a report on Wednesday, April 8th. Weiss Ratings downgraded shares of Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Finally, Canaccord Genuity Group dropped their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.23.

Hedge Funds Weigh In On Privia Health Group

Several institutional investors have recently modified their holdings of the business. Great Lakes Advisors LLC acquired a new position in shares of Privia Health Group during the third quarter worth $4,487,000. ArrowMark Colorado Holdings LLC acquired a new stake in Privia Health Group in the third quarter valued at $8,750,000. Royce & Associates LP lifted its holdings in Privia Health Group by 54.5% during the 3rd quarter. Royce & Associates LP now owns 607,191 shares of the company’s stock worth $15,119,000 after buying an additional 214,166 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in Privia Health Group by 25.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 450,010 shares of the company’s stock worth $11,205,000 after buying an additional 92,507 shares during the last quarter. Finally, Summit Global Investments lifted its holdings in Privia Health Group by 273.9% during the 3rd quarter. Summit Global Investments now owns 33,677 shares of the company’s stock worth $839,000 after buying an additional 24,670 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.